Back to HomeKorea StockPremium

Kolon TissueGene (950160.KQ) Q1 2026: ₩99.9B Net Loss Is 95% Non-Cash Derivatives as TG-C Phase 3 Misses Primary Endpoints

Jul 23, 2026

The accounting headline masks a stabilizing cash burn — but ₩355.8 billion in capitalized development costs now faces its most consequential impairment test as the second Phase 3 readout approaches in October.

Source: Q1 2026 Quarterly Report (28th Fiscal Year, January 1 – March 31, 2026) — Filed May 15, 2026 with DART | Standalone (Non-Consolidated) Financial Statements; no consolidated statements exist as the company has no subsidiaries | Functional and Presentation Currency: USD; ₩ figures translated at period-end rate (balance sheet) and average rate (income statement / cash flows) | Unit: ₩ billions

Unlimited U.S.-market analysis, $9.99/month

“Kolon TissueGene (950160.KQ) Q1 2026: ₩99.9B Net Loss Is 95% Non-Cash Derivatives as TG-C Phase 3 Misses Primary Endpoints”

This article became available on July 23, 2026. Subscribe to read in full, or wait until October 21, 2026 when it becomes free.

Subscribe — $9.99/month

Cancel anytime. Full refund within 7 days.

Access is tied to your account. Subscribe with the same email you sign up with — if you already paid, sign up with that email and it unlocks automatically.

NewsFinanceMarkets

Go deeper than the headline

You just read what happened. Here's how to read what it means.

Free daily briefing

The U.S. market, every morning — free

LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.

Get LineVest Daily — free →

This company

Full report on Kolon TissueGene

We read Kolon TissueGene's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.

$12 · one-time

Get the Kolon TissueGene report

Every name you watch

Follow the whole market

Reading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.

$9.99 · monthly

Independent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.

Kolon TissueGene (950160.KQ) Q1 2026: ₩99.9B Net Loss Is 95% Non-Cash Derivatives as TG-C Phase 3 Misses Primary Endpoints

Unlimited U.S.-market analysis, $9.99/month

Go deeper than the headline

The U.S. market, every morning — free

Full report on Kolon TissueGene

Follow the whole market

Related Stories

How to Read Korean DART Filings in English: A Guide for Foreign Investors

Samsung Electronics Q2 2026: Record KRW 89.5T Profit as MX Posts First Smartphone Loss Since 2011

Celltrion Amends Q2 2026 Earnings Filing, Confirms Record ₩430B Operating Profit

ABL Bio (298380.KQ) Q1 2026: Loss Narrows 48%, ₩186.7B in Cash

EO Technics (039030.KQ) Q1 2026: Operating Profit Doubles as HBM Laser Demand Surges

Samchundang Pharmaceutical (000250.KS) FY2025: Ailia Biosimilar Debut Drives 220% Operating Profit Surge, Swings to Net Profit

OCI Holdings (010060.KS) Q2 2026: Texas Solar Drives 58% Revenue Jump and Third Straight Quarterly Profit

Jusung Engineering (036930.KQ) Q1 2026: Revenue Halves to ₩54.9B as R&D at 46% of Sales Drives ₩7B Operating Loss

Rainbow Robotics (277810.KQ) Q1 2026: Revenue Surges 116.6% as Samsung Subsidy Lifts Scale, But R&D Intensity Widens Operating Loss

Alteogen (196170.KQ) Q1 2026: 120% SG&A Surge Erodes Operating Profit 36% Despite ₩867.5B Biogen Deal

EcoPro (086520.KQ) Q1 2026: ₩247.3B Swing, Gross Margin Doubles

EcoPro BM (247540.KQ) Q1 2026: Profit Surges 9x, Margin Now Real